We have located links that may give you full text access.
Effect of Repeated Administration of Cefquinome on Biochemical and Hematological Parameters in Buffalo Calves.
Toxicology International 2015 January
AIM: Cefquinome, a fourth generation of cephalosporins have been developed for use in animals. Similar to other species, it may also have some adverse reactions in buffalo calves at therapeutic dosage. In the present study, effect of repeated administration of cefquinome on biochemical and hematological parameters was studied in buffalo calves.
MATERIALS AND METHODS: Animals were divided into two groups having three animals in each group. Group 1 was kept as control and animals of Group 2 were given cefquinome at dose rate of 2 mg.kg(-1) body weight by intramuscular route for continuously 7 days. Blood samples were collected daily and 3 days post treatment.
RESULTS: The values of aspartate aminotransferase (AST), alanine aminotransferase (ALT), gamma-glutamyl transpeptidase (GGTP), and alkaline phosphatase (ALKP) in control animals were in the range of 127.7-148.3 IU/L,49.0-55.6 IU/L, 14.0-17.3 IU/L, and 111.0-134.3 IU/L, respectively. The repeated administration of cefquinome did not influence the plasma activities of AST, ALT, GGTP, and ALKP in treated animals. The level of blood urea nitrogen (BUN) and creatinine before treatment was 14.3 ± 0.88 mg/dl and1.70 ± 0.04 mg/dl, which significantly increased on 3(rd) day (21.0 ± 1.53 mg/dl) and 2(nd) day (2.33 ± 0.07 mg/dl), respectively. Among hematological parameters, there was significant variation in levels of hemoglobin (Hb), total erythrocyte count (TEC), erythrocyte sedimentation rate (ESR), mean corpuscular volume (MCV), mean corpuscular hemoglobin (MCH), and mean corpuscular hemoglobin concentration (MCHC) in treated animals. No abnormal clinical symptoms were observed in any animal.
CONCLUSION: The results revealed that clinically, the therapy of cefquinome may be continued up to 7 days.
MATERIALS AND METHODS: Animals were divided into two groups having three animals in each group. Group 1 was kept as control and animals of Group 2 were given cefquinome at dose rate of 2 mg.kg(-1) body weight by intramuscular route for continuously 7 days. Blood samples were collected daily and 3 days post treatment.
RESULTS: The values of aspartate aminotransferase (AST), alanine aminotransferase (ALT), gamma-glutamyl transpeptidase (GGTP), and alkaline phosphatase (ALKP) in control animals were in the range of 127.7-148.3 IU/L,49.0-55.6 IU/L, 14.0-17.3 IU/L, and 111.0-134.3 IU/L, respectively. The repeated administration of cefquinome did not influence the plasma activities of AST, ALT, GGTP, and ALKP in treated animals. The level of blood urea nitrogen (BUN) and creatinine before treatment was 14.3 ± 0.88 mg/dl and1.70 ± 0.04 mg/dl, which significantly increased on 3(rd) day (21.0 ± 1.53 mg/dl) and 2(nd) day (2.33 ± 0.07 mg/dl), respectively. Among hematological parameters, there was significant variation in levels of hemoglobin (Hb), total erythrocyte count (TEC), erythrocyte sedimentation rate (ESR), mean corpuscular volume (MCV), mean corpuscular hemoglobin (MCH), and mean corpuscular hemoglobin concentration (MCHC) in treated animals. No abnormal clinical symptoms were observed in any animal.
CONCLUSION: The results revealed that clinically, the therapy of cefquinome may be continued up to 7 days.
Full text links
Related Resources
Trending Papers
Challenges in Septic Shock: From New Hemodynamics to Blood Purification Therapies.Journal of Personalized Medicine 2024 Februrary 4
Molecular Targets of Novel Therapeutics for Diabetic Kidney Disease: A New Era of Nephroprotection.International Journal of Molecular Sciences 2024 April 4
The 'Ten Commandments' for the 2023 European Society of Cardiology guidelines for the management of endocarditis.European Heart Journal 2024 April 18
A Guide to the Use of Vasopressors and Inotropes for Patients in Shock.Journal of Intensive Care Medicine 2024 April 14
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app